Statera Biopharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Unrealized currency gain on short-term investments
Investment loss provision
Non-cash compensation
Depreciation expense
Amortization expense
Impairment loss
Legal settlement
Stock based compensation
Realized foreign currency translation
Accrued liability extinguishment
Change in value of warrant liability
Noncash interest expense
Noncash lease expense
Services obtained for common shares
Restricted Stock
Total services obtained for common shares
Common Stock issued for license agreement
Asumption of debt in exchange for license agreement

Changes in operating assets and liabilities:
Accounts receivable and other current assets
Other long-term assets
Accounts payable and accrued expenses

Net cash used in operating activities
Other current assets
Accounts receivable
Short term investments
Due from subsidiary
Prepaid expenses
Contract asset
Contract liability
Deferred revenue
Accrued expenses
Stock issuances due
Investment in subsidiary
Liabilities of discontinued operations
Accounts payable and accrued expenses
Net cash used in operating activities
Cash flows from investing activities:
Purchase of short-term investments
Sale of short-term investments
Proceeds from sale of equipment
Purchase of equipment
Decrease in restricted cash
Net proceeds from sale of treasury stock
Purchase of property and equipment
Cash acquired, acquisition
ImQuest
CBLI
Net cash provided by investing activities

Cash flows from financing activities:
Issuance of common stock, net of offering costs
Exercise of warrants
Proceeds from issuance of Common
Common Stock issued for license agreement
Proceeds from issuance of Preferred shares
Proceeds from issuance of Common Stock Due
Proceeds from advance from related party
Repayments on notes payable
Payment of offering costs
Payment of debt issuance costs
Proceeds from issuance of long-term debt
Net cash provided by financing activities
Decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Effect of exchange rate change on cash and equivalents
Increase (decrease) in cash and cash equivalents
Cash, cash equivalents, and restricted cash, beginning of year
Cash, cash equivalents, and restricted cash end of year
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid during the period for interest
Cash paid for interest

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Cashless exercise of warrants
Right of use asset exchanged for lease liability
Shares to be issued for services
Debt principal converted to equity
Noncontrolling interest acquired
Common stock issued for conversion of debt
Common stock issued as a modification of debt terms

Comments